Physician profile
Daniel T Burzon
NPI 1134102015
$3,990.30
in general payments reported to CMS, 2019-2025
39 companies · $916 in 2025
The $916 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $613 · 2021: $517 · 2022: $427 · 2023: $265 · 2024: $327 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $734.89 | 2020-2023 | Axonics, Bulkamid |
| Medtronic, INC. | $519.19 | 2022-2025 | Interstim |
| Neotract INC. | $281.98 | 2019 | |
| Medtronic USA, INC. | $243.44 | 2019 | |
| Calyxo, INC. | $233.76 | 2025 | Cvac Aspiration System |
| Edap Technomed INC | $198.08 | 2025 | |
| Teleflex LLC | $184.04 | 2022-2024 | |
| Pfizer INC. | $155.27 | 2019-2023 | |
| Astellas Pharma US INC | $119.78 | 2019-2023 | Xtandi |
| Merck Sharp & Dohme LLC | $116.01 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Myovant Sciences INC. | $112.81 | 2021-2022 | |
| Janssen Biotech, INC. | $112.03 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Innovation Technologies INC | $107.01 | 2021 | |
| Boston Scientific Corporation | $101.06 | 2019-2025 | Rezum Generator, Axonics |
| Palette Life Sciences, INC. | $81.89 | 2023 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Burzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.